AU2014267360B2 - N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors - Google Patents
N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors Download PDFInfo
- Publication number
- AU2014267360B2 AU2014267360B2 AU2014267360A AU2014267360A AU2014267360B2 AU 2014267360 B2 AU2014267360 B2 AU 2014267360B2 AU 2014267360 A AU2014267360 A AU 2014267360A AU 2014267360 A AU2014267360 A AU 2014267360A AU 2014267360 B2 AU2014267360 B2 AU 2014267360B2
- Authority
- AU
- Australia
- Prior art keywords
- chloro
- hydroxypyridin
- sulfonamide
- methanesulfonamide
- dichlorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c1cc(C(N)=C)c(*)[n]1 Chemical compound *c1cc(C(N)=C)c(*)[n]1 0.000 description 4
- HTMNVTPAFIJGFS-UHFFFAOYSA-N CC(C)(c(nc1)cc(O)c1NS(Cc(cc1)cc(Cl)c1Cl)(=O)=O)F Chemical compound CC(C)(c(nc1)cc(O)c1NS(Cc(cc1)cc(Cl)c1Cl)(=O)=O)F HTMNVTPAFIJGFS-UHFFFAOYSA-N 0.000 description 1
- MXRZSJRXWPRJSZ-UHFFFAOYSA-N CCCc(cc1)ccc1S(Nc(ccc(Cl)n1)c1O)(=O)=O Chemical compound CCCc(cc1)ccc1S(Nc(ccc(Cl)n1)c1O)(=O)=O MXRZSJRXWPRJSZ-UHFFFAOYSA-N 0.000 description 1
- RDICPHNGEZKDQS-UHFFFAOYSA-N CCN(CC)C(c1cccc(S(Nc2ncc(C)nc2O)(=O)=O)c1)=O Chemical compound CCN(CC)C(c1cccc(S(Nc2ncc(C)nc2O)(=O)=O)c1)=O RDICPHNGEZKDQS-UHFFFAOYSA-N 0.000 description 1
- SXMFSKHZGSWIIJ-UHFFFAOYSA-N COc(ncc(S(Nc(cncc1)c1O)(=O)=O)c1)c1Br Chemical compound COc(ncc(S(Nc(cncc1)c1O)(=O)=O)c1)c1Br SXMFSKHZGSWIIJ-UHFFFAOYSA-N 0.000 description 1
- VPFWSOVXTMGFBG-UHFFFAOYSA-N COc(ncc(S(Nc(nnc(Cl)c1)c1O)(=O)=O)c1)c1Br Chemical compound COc(ncc(S(Nc(nnc(Cl)c1)c1O)(=O)=O)c1)c1Br VPFWSOVXTMGFBG-UHFFFAOYSA-N 0.000 description 1
- XUCLWPUKHUHMOU-UHFFFAOYSA-N CS(c(nc1)cc(O)c1NS(c1cc(Cl)cc(Cl)c1)(=O)=O)(=O)=O Chemical compound CS(c(nc1)cc(O)c1NS(c1cc(Cl)cc(Cl)c1)(=O)=O)(=O)=O XUCLWPUKHUHMOU-UHFFFAOYSA-N 0.000 description 1
- NQYKJLDYIFCZPM-UHFFFAOYSA-N CS(c1cc(O)c(NS(Cc2cc(Cl)cc(Cl)c2)(=O)=O)nn1)(=O)=O Chemical compound CS(c1cc(O)c(NS(Cc2cc(Cl)cc(Cl)c2)(=O)=O)nn1)(=O)=O NQYKJLDYIFCZPM-UHFFFAOYSA-N 0.000 description 1
- NEEPFYZFYICLBU-UHFFFAOYSA-N Cc1cc(C)cc(S(Nc(ncc(S(C)(=O)=O)n2)c2O)(=O)=O)c1 Chemical compound Cc1cc(C)cc(S(Nc(ncc(S(C)(=O)=O)n2)c2O)(=O)=O)c1 NEEPFYZFYICLBU-UHFFFAOYSA-N 0.000 description 1
- MGUPDRHILDSXNQ-UHFFFAOYSA-N N#Cc1cc(CS(Nc(ncc(Cl)c2)c2O)(=O)=O)cc(Cl)c1 Chemical compound N#Cc1cc(CS(Nc(ncc(Cl)c2)c2O)(=O)=O)cc(Cl)c1 MGUPDRHILDSXNQ-UHFFFAOYSA-N 0.000 description 1
- QRKAVNWNTFRNCH-UHFFFAOYSA-N Oc(c(Cl)ncc1)c1NS(c1cc(Cl)cc(Cl)c1)(=O)=O Chemical compound Oc(c(Cl)ncc1)c1NS(c1cc(Cl)cc(Cl)c1)(=O)=O QRKAVNWNTFRNCH-UHFFFAOYSA-N 0.000 description 1
- VFNCEUUAQRLOSU-UHFFFAOYSA-N Oc(cn1)c(NS(c2cc(Cl)cc(Cl)c2)(=O)=O)nc1Cl Chemical compound Oc(cn1)c(NS(c2cc(Cl)cc(Cl)c2)(=O)=O)nc1Cl VFNCEUUAQRLOSU-UHFFFAOYSA-N 0.000 description 1
- MJTOXIWLYKHMFP-UHFFFAOYSA-N Oc1c(NS(Cc2cnccc2)(=O)=O)ncc(Cl)c1 Chemical compound Oc1c(NS(Cc2cnccc2)(=O)=O)ncc(Cl)c1 MJTOXIWLYKHMFP-UHFFFAOYSA-N 0.000 description 1
- LJJNPVSKEIECKO-UHFFFAOYSA-N Oc1cc(Cl)cnc1NS(Cc(cc1)cc(F)c1F)(=O)=O Chemical compound Oc1cc(Cl)cnc1NS(Cc(cc1)cc(F)c1F)(=O)=O LJJNPVSKEIECKO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13167680.1 | 2013-05-14 | ||
| EP13167680 | 2013-05-14 | ||
| PCT/EP2014/059829 WO2014184234A1 (en) | 2013-05-14 | 2014-05-14 | N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014267360A1 AU2014267360A1 (en) | 2015-12-17 |
| AU2014267360B2 true AU2014267360B2 (en) | 2018-07-05 |
Family
ID=48366235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014267360A Ceased AU2014267360B2 (en) | 2013-05-14 | 2014-05-14 | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9873687B2 (enExample) |
| EP (1) | EP2925743B1 (enExample) |
| JP (1) | JP6322280B2 (enExample) |
| KR (1) | KR20160006717A (enExample) |
| CN (1) | CN105377837B (enExample) |
| AU (1) | AU2014267360B2 (enExample) |
| BR (1) | BR112015027395A2 (enExample) |
| CA (1) | CA2912313A1 (enExample) |
| EA (1) | EA028512B1 (enExample) |
| ES (1) | ES2563902T3 (enExample) |
| MX (1) | MX360455B (enExample) |
| WO (1) | WO2014184234A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220378763A1 (en) * | 2019-06-28 | 2022-12-01 | Calprotect Ab | Compound for treatment of acute inflammation in the myocardium |
| CN110407721A (zh) * | 2019-08-13 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法 |
| CN112480106B (zh) * | 2020-11-17 | 2022-09-02 | 南京海纳医药科技股份有限公司 | 一种马来酸阿伐曲泊帕杂质的制备方法 |
| CN115974772B (zh) * | 2023-01-05 | 2024-06-14 | 山东铂源药业股份有限公司 | 一种利用微通道反应器制备吡啶-3-磺酰氯的方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313806A (en) | 1963-07-01 | 1967-04-11 | Sumitomo Chemical Co | Sulfanilylaminopyridazinone derivatives and method for their production |
| AU6944696A (en) * | 1995-09-14 | 1997-04-01 | Shionogi & Co., Ltd. | Novel phenylacetic acid derivatives and medicinal composition containing the same |
| AU2002358390A1 (en) * | 2001-12-18 | 2003-06-30 | Astrazeneca Ab | Novel compounds |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| US8053477B2 (en) * | 2002-03-29 | 2011-11-08 | University Of Maryland, Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
| US20060004085A1 (en) | 2002-03-29 | 2006-01-05 | University Of Maryland , Baltimore | Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same |
| SE0301654D0 (sv) | 2003-06-05 | 2003-06-05 | Astrazeneca Ab | Novel compounds |
| EP1661889A4 (en) | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES |
| US7767687B2 (en) | 2004-12-13 | 2010-08-03 | Biogen Idec Ma Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
| AR053992A1 (es) | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2006122723A1 (en) * | 2005-05-19 | 2006-11-23 | Vaecgene Biotech Gmbh | Method for the prevention and/or treatment of autoimmune disease or allogeneic transplant rejections |
| ZA200801822B (en) | 2005-08-26 | 2009-09-30 | Serono Lab | Pyrazine derivatives and use as p13k inhibitors |
| GB0524786D0 (en) * | 2005-12-05 | 2006-01-11 | Glaxo Group Ltd | Compounds |
| JP5483880B2 (ja) | 2006-10-23 | 2014-05-07 | 武田薬品工業株式会社 | イミノピリジン誘導体およびその用途 |
| WO2010100127A1 (en) | 2009-03-04 | 2010-09-10 | Novartis Ag | Disubstituted imidazole derivatives as modulators of raf kinase |
| CA2762680C (en) | 2009-05-21 | 2018-04-17 | Chlorion Pharma, Inc. | Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics |
| EA201200321A1 (ru) | 2009-08-26 | 2012-09-28 | Новартис Аг | Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4 |
| US20110160200A1 (en) * | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
| KR20130027080A (ko) | 2010-01-06 | 2013-03-14 | 에리코, 조셉, 피. | 표적화된 약물 개발 방법 및 조성물 |
| US9006433B2 (en) | 2010-04-21 | 2015-04-14 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| WO2012035171A2 (en) | 2010-09-17 | 2012-03-22 | Kancera Ab | New compounds |
-
2014
- 2014-05-14 AU AU2014267360A patent/AU2014267360B2/en not_active Ceased
- 2014-05-14 BR BR112015027395A patent/BR112015027395A2/pt not_active Application Discontinuation
- 2014-05-14 WO PCT/EP2014/059829 patent/WO2014184234A1/en not_active Ceased
- 2014-05-14 EP EP14723807.5A patent/EP2925743B1/en active Active
- 2014-05-14 ES ES14723807.5T patent/ES2563902T3/es active Active
- 2014-05-14 CA CA2912313A patent/CA2912313A1/en not_active Abandoned
- 2014-05-14 CN CN201480027366.6A patent/CN105377837B/zh not_active Expired - Fee Related
- 2014-05-14 EA EA201592166A patent/EA028512B1/ru not_active IP Right Cessation
- 2014-05-14 JP JP2016513346A patent/JP6322280B2/ja not_active Expired - Fee Related
- 2014-05-14 KR KR1020157034181A patent/KR20160006717A/ko not_active Withdrawn
- 2014-05-14 US US14/890,938 patent/US9873687B2/en not_active Expired - Fee Related
- 2014-05-14 MX MX2015015741A patent/MX360455B/es active IP Right Grant
-
2017
- 2017-12-08 US US15/836,036 patent/US10125125B2/en active Active
Non-Patent Citations (1)
| Title |
|---|
| PECORARI P ET AL, "Compounds with potential anticancer activity benzenesulfonamido-Pyrimidine derivatives", FARMACO, EDIZIONE SCIENTIFICA, SOCIETA CHIMICA ITALIANA, PAVIA, IT, (1987-01-01), vol. 42, no. 7, ISSN 0430-0920, pages 499 - 503 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9873687B2 (en) | 2018-01-23 |
| US20180155330A1 (en) | 2018-06-07 |
| HK1213254A1 (en) | 2016-06-30 |
| JP6322280B2 (ja) | 2018-05-09 |
| ES2563902T3 (es) | 2016-03-16 |
| JP2016518428A (ja) | 2016-06-23 |
| EP2925743B1 (en) | 2016-02-03 |
| EP2925743A1 (en) | 2015-10-07 |
| AU2014267360A1 (en) | 2015-12-17 |
| CN105377837A (zh) | 2016-03-02 |
| CN105377837B (zh) | 2017-08-04 |
| MX360455B (es) | 2018-11-01 |
| US10125125B2 (en) | 2018-11-13 |
| BR112015027395A2 (pt) | 2017-08-29 |
| KR20160006717A (ko) | 2016-01-19 |
| EA201592166A1 (ru) | 2016-05-31 |
| CA2912313A1 (en) | 2014-11-20 |
| WO2014184234A1 (en) | 2014-11-20 |
| EA028512B1 (ru) | 2017-11-30 |
| MX2015015741A (es) | 2016-03-16 |
| US20160115158A1 (en) | 2016-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5643312B2 (ja) | カリウムイオンチャネルインヒビターとしてのキナゾリン | |
| CN106458930B (zh) | 2-氨基嘧啶类化合物及其药物组合物和应用 | |
| CN105492438B (zh) | 磺亚胺取代的5-氟-n-(吡啶-2-基)吡啶-2-胺衍生物以及其作为cdk9激酶抑制剂的用途 | |
| JP2020158523A (ja) | 新規ヒストンデアセチラーゼインヒビター | |
| JP2022530097A (ja) | がんを処置するためのアシルスルホンアミド類 | |
| US10125125B2 (en) | N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors | |
| JP2012507551A (ja) | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 | |
| TW201105326A (en) | Diamino heterocyclic carboxamide compound | |
| WO2019012172A1 (es) | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2) | |
| JP6969800B2 (ja) | 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体 | |
| TW201512171A (zh) | 化學化合物 | |
| KR102636651B1 (ko) | 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도 | |
| EA036542B1 (ru) | Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора | |
| WO2014003124A1 (ja) | 新規なアミド誘導体またはその塩 | |
| ES2985416T3 (es) | Nuevos compuestos potentes y selectivos como moduladores del receptor de serotonina 1B | |
| JPWO2008018529A1 (ja) | 新規なベンジル（ピリジルメチル）アミン構造を有するピリミジン化合物及びこれを含有する医薬 | |
| KR20220156890A (ko) | Phd 억제제 화합물, 조성물, 및 용도 | |
| CN107001341B (zh) | 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物 | |
| TW200812979A (en) | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | |
| KR20170016921A (ko) | 항증식성 화합물로서 1h-1, 8-나프티리딘-2-원 | |
| HK1213254B (en) | N-(heteroaryl)-sulfonamide derivatives useful as s100-inhibitors | |
| KR101920163B1 (ko) | 항암용 약학 조성물 | |
| WO2017097215A1 (zh) | 内嵌脲类结构的wnt通路抑制剂 | |
| CN116284043A (zh) | 三环类化合物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |